QUEEN MARY UNIVERSITY OF LONDON
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Private
- Established
- 1882-01-08
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.qmul.ac.uk
New bioMarkers tO straTIfy cOlorectal caNcer Referrals
Not yet recruiting
- Conditions
- Colorectal CarcinomaPolypColorectal Adenoma
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 582
- Registration Number
- NCT07035691
- Locations
- π¬π§
Barts Health NHS Trust, London, England, United Kingdom
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
Not Applicable
Not yet recruiting
- Conditions
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)MASH - Metabolic Dysfunction-Associated SteatohepatitisMASH With FibrosisMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseSteatosis of Liver
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 72
- Registration Number
- NCT07013916
- Locations
- π¬π§
Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
The Effect of IPD on Lateral Bone Augmentation
Not Applicable
Not yet recruiting
- Conditions
- Guided Bone RegenerationBone ResorptionDiagnostic Imaging
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 12
- Registration Number
- NCT06999915
- Locations
- π¬π§
Barts Health NHS Trust Dental Hospital, London, United Kingdom
Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study
Not yet recruiting
- Conditions
- Prostate CA
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 500
- Registration Number
- NCT06987045
An Imaging Study in ER Negative Breast Cancer by Targeting Ξ±vΞ²6
Not Applicable
Withdrawn
- Conditions
- Breast Cancer
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Queen Mary University of London
- Registration Number
- NCT06978478
- Locations
- π¬π§
Barts Health NHS Trust, London, United Kingdom
Left Ventricular Thrombus Registry
Recruiting
- Conditions
- Left Ventricular Thrombus
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 1500
- Registration Number
- NCT06963567
- Locations
- π¬π§
St Bartholomew's Hospital, London, United Kingdom
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: Datopotamab Deruxtecan (Dato-DXd)
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 140
- Registration Number
- NCT06954480
- Locations
- π¬π§
Barts Cancer Institute, Centre of Experimental Cancer Medicine, London, United Kingdom
Delivery and Implementation of a Randomised Crossover Trial on Thrombosis
Not Applicable
Not yet recruiting
- Conditions
- Hip FracturesVenous Thromboembolism (VTE)
- Interventions
- Drug: Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery.Drug: Low molecular weight heparin (LMWH)
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 21194
- Registration Number
- NCT06937372
Hyperthermic Intra-Vesical Chemotherapy
Not Applicable
Completed
- Conditions
- Bladder Cancer
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 259
- Registration Number
- NCT06768346
- Locations
- π¬π§
Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom
π¬π§Western General Hospital, Edinburgh, Edinburgh, United Kingdom
π¬π§Royal Surrey County Hospital NHS Foudation Trust, Guildford, United Kingdom
Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 320
- Registration Number
- NCT06892860
- Locations
- π«π·
Unicancer, Paris, France
πͺπΈAdknoma, Madrid, Spain
π¬π§Barts Health NHS Trust, London, United Kingdom